Endocrine Abstracts

Introduction: Obesity today is a growing epidemic throughout the world. With weight gain, the risk of type 2 diabetes and hypertension increases. With the approval of GLP-1 RA (semaglutide) by the FDA in June 2021 for weight reduction, a big push was given regarding the possibilities of obesity and especially for people at high risk of developing type 2 diabetes.Aim: To analyze the impact of semaglutide on insulin resistance and weight loss in patients w...